参考文献/References:
[1]Zheng B,Shen H,Han H,et al.Dietary fiber intake and reduced risk of ovarian cancer:a meta-analysis[J].Nutr J,2018,17(1):99. [2]Kathawala RJ,Kudelka A,Rigas B.The Chemoprevention of Ovarian Cancer:the Need and the Options[J].Current Pharmacology Reports,2018,4(3):250-260. [3]Markowska A,Sajdak S,Huczyński A,et al.Ovarian cancer stem cells:A target for oncological therapy[J].Adv Clin Exp Med,2018,27(7):1017-1020. [4]Lupia M,Cavallaro U.Ovarian cancer stem cells:still an elusive entity[J].Mol Cancer,2017,16(1):64. [5]Chan HL,Morey L.Emerging Roles for Polycomb-Group Proteins in Stem Cells and Cancer[J].Trends Biochem Sci,2019,44(8):688-700. [6]Di Carlo V,Mocavini I,Di Croce L.Polycomb complexes in normal and malignant hematopoiesis[J].The Journal of Cell Biology,2019,218(1):55-69. [7]Kouznetsova VL,Tchekanov A,Li X,et al.Polycomb repressive 2 complex-Molecular mechanisms of function[J].Protein Sci,2019,28(8):1387-1399. [8]Brand M,Nakka K,Zhu J,et al.Polycomb/Trithorax Antagonism:Cellular Memory in Stem Cell Fate and Function[J].Cell Stem Cell,2019,24(4):518-533. [9]Sahasrabuddhe AA.BMI1:A Biomarker of Hematologic Malignancies[J].Biomark Cancer,2016(8):65-75. [10]Gray F,Cho HJ,Shukla S,et al.BMI1 regulates PRC1 architecture and activity through homo-and hetero-oligomerization[J].Nat Commun,2016(7):13343. [11]Bhattacharya R,Banerjee Mustafi S,Street M,et al.Bmi-1:At the crossroads of physiological and pathological biology[J].Genes&Diseases,2015,2(3):225-239. [12]Storti B,Civita S,Faraci P,et al.Fluorescence imaging of biochemical relationship between ubiquitinated histone 2A and Polycomb complex protein BMI1[J].Biophys Chem,2019(253):106225. [13]Abd El Hafez A,El-Hadaad HA.Immunohistochemical expression and prognostic relevance of Bmi-1,a stem cell factor,in epithelial ovarian cancer[J].Ann Diagn Pathol,2014,18(2):58-62. [14]Wang JL,Wu JH,CH.Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions:An in vivo and in vitro study[J].Pathol Res Pract,2017,213(12):1542-1551. [15]Yang G,He W,Cai M,et al.Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma[J].BMC Cancer,2010,10(1):133. [16]Kim BR,Kwon Y,Rho SB.BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death[J].Oncol Rep,2017,37(1):579-586. [17]Kim B,Seo SH,Park MS,et al.sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways[J].Oncotarget,2015,6(31):31380. [18]Takeda Y,Mori T,Imabayashi H,et al.Can the life span of human marrow stromal cells be prolonged by bmi-1,E6,E7,and/or telomerase without affecting cardiomyogenic differentiation[J].The Journal of Gene Medicine,2004,6(8):833-845. [19]Zhang FB,Sui LH,Xin T.Correlation of Bmi-1 expression and telomerase activity in human ovarian cancer[J].Brit J Biomed Sci,2008,65(4):172-177. [20]Zhang XL,Sun BL,Tian SX,et al.MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1[J].Eur Rev Med Pharmacol Sci,2019,23(9):3635-3644. [21]Dey A,Xiong X,Crim A,et al.Evaluating the Mechanism and Therapeutic Potential of PTC-028,a Novel Inhibitor of BMI-1 Function in Ovarian Cancer[J].Mol Cancer Ther,2018,17(1):39-49. [22]吕缜一,陆昌瑞.人源CBX7全长及部分片段的表达纯化及单体结构研究[J].生物化工,2018,4(1):1-4. [23]Federico A,Sepe R,Cozzolino F,et al.The complex CBX7-PRMT1 has a critical role in regulating E-cadherin gene expression and cell migration[J].Gene Regulatory Mechanisms,2019,1862(4):509-521. [24]关珊丽.多梳蛋白CBX家族成员间的分子互作初步研究[D].兰州大学,2017. [25]廖艳丹,韩庆.CBX7蛋白在卵巢癌组织中的表达及意义[J].重庆医学,2012,41(20):2045-2046. [26]廖艳丹,韩庆.CBX7 mRNA在卵巢癌组织中的表达及意义[J].中国医药导报,2012,9(15):37-38. [27]高尚.CBX7在卵巢浆液性上皮性肿瘤中的表达及意义[D].中国医科大学,2015. [28]Shinjo K,Yamashita Y,Yamamoto E,et al.Expression of chromobox homolog 7(CBX7)is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation[J].Int J Cancer,2014,135(2):308-318. [29]Mu W,Starmer J,Yee D,et al.EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation[J].Epigenet Chromatin,2018,11(1):71. [30]Kim KH,Roberts CWM.Targeting EZH2 in cancer[J].Nat Med,2016,22(2):128-134. [31]Martinez-Canales S,Lopez DRM,Nuncia-Cantarero M,et al.Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer[J].Cancer Med,2018,7(5):1896-1907. [32]Guo J,Cai J,Yu L,et al.EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo[J].Cancer Sci,2011,102(3):530-539. [33]Lu F,Xu H,Wang Q,et al.Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo[J].Oncol Lett,2018,15(3):3233-3239. [34]Zeng XY,Jiang XY,Yong JH,et al.lncRNA ABHD11-AS1,regulated by the EGFR pathway,contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2[J].Cancer Med,2019,8(16):7074-7085. [35]Jones BA,Varambally S,Arend RC.Histone Methyltransferase EZH2:A Therapeutic Target for Ovarian Cancer[J].Mol Cancer Ther,2018,17(3):591-602. [36]Yi X,Guo J,Guo J,et al.EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion[J].Sci Rep,2017,7(1):3568. [37]Hu S,Yu L,Li Z,et al.Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo[J].Cancer Biol Ther,2014,10(8):788-795. [38]Sun Y,Jin L,Liu J,et al.Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy[J].Cancer Biother Radio,2016,31(7):246-252.
相似文献/References:
[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,31(01):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Medical Information,2019,32(01):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,32(01):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(01):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,32(01):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(01):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Medical Information,2019,32(01):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[8]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Medical Information,2019,32(01):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[9]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Medical Information,2020,33(01):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
[10]张小红.以自我管理为导向的5A护理模式对卵巢癌患者自我效能与负性情绪的影响[J].医学信息,2020,33(03):186.[doi:10.3969/j.issn.1006-1959.2020.03.063]
ZHANG Xiao-hong.Effect of 5A Nursing Model Oriented on Self-management on Self-efficacy and Negative Emotions of Patients with Ovarian Cancer[J].Medical Information,2020,33(01):186.[doi:10.3969/j.issn.1006-1959.2020.03.063]